Since auranofin is FDA-approved for human use in gold-conjugated form to treat rheumatoid arthritis [57], its apparent effect on apicomplexan IMPα documented here, together with its robust antiparasitic effects against P. falciparum and T. gondii, indicate its potential for future investigation as an antiparasitic for malaria and toxoplasmosis. This evidence concerns the gene IMPA1 and toxoplasmosis.